Additionally, Cluster 3 showed worse liver function (median AST 61.25 vs. 25.25 [Cluster 1]/29.05 [Cluster 2] IU/L;median r-GGT 85.35 vs. 30.95 [Cluster 1]/30.35 [Cluster 2] IU/L), higher inflammatory markers (median CRP 31.6 vs. 4.0 [Cluster 1]/0.75 [Cluster 2] mg/L) and higher tumor profile (median AFP 402.95 vs. 5.5 [Cluster 1]/5.06 [Cluster 2]ng/ml). The gene discussed is AFP; the disease is neoplasm.